Additional S1P receptor modulators have recently become available for MS treatment that do not require phosphorylation, including the S1P1,5-selective modulators, ozanimod and siponimod (BAF312; Chun et al., 2021). The gene discussed is S1PR1; the disease is myeloid sarcoma.